Every Time a State Schedules One Sedative, the Drug Supply Finds Another. Medetomidine Is What’s Next.

In Philadelphia, drug-checking labs have been watching one number flip almost completely in under two years. In May 2024, xylazine — the veterinary sedative that turned “tranq” into a household word and left users with the wound crisis that made national news — showed up in 97% of dope samples tested. By March 2026, that number had collapsed to 28%. Medetomidine, a different veterinary sedative most people have never heard of, went the other direction: from 29% of samples to 90%, according to reporting from North Carolina Health News drawing on UNC’s street drug lab data.

A drug supply doesn’t get safer when you schedule its ingredients. It gets rearranged.

That’s the plain read of what happened. Xylazine wasn’t eliminated from the market — it was legislated out of favor as more states scheduled it as a controlled substance, and suppliers who needed something to stretch and sedate their fentanyl found a substitute sitting on the shelf: medetomidine, a drug used by veterinarians to sedate large animals, up to 300 times more potent than xylazine by weight. If you or someone you know has needed multiple doses of naloxone to reverse a recent overdose and it felt different than it used to, this is very possibly why. Medetomidine isn’t an opioid. Naloxone doesn’t touch it. It works on a different receptor system entirely, which means the standard overdose response — more naloxone, faster — doesn’t fully address what’s actually causing someone to stop breathing when medetomidine is in the mix.

The pattern is older than this drug

We have watched this exact shape of failure before, and it has a name in federal law. In 1986, Congress passed the Controlled Substance Analogue Enforcement Act specifically because clandestine chemists kept staying one small molecular tweak ahead of whatever the DEA had just scheduled — a “designer drug” arms race that the law was built to shortcut by treating any “substantially similar” compound as if it were already controlled. By 2013, the DEA itself was telling Congress the Analogue Act no longer deterred large-scale synthesis of new compounds. Forty years later, the mechanism is identical, just faster: schedule the sedative, the supply finds the next sedative, the naloxone that used to be enough stops being enough, and the field spends a year figuring out why overdoses stopped responding the way they used to.

The DEA’s own May 2026 advisory names the current cluster explicitly: fentanyl increasingly mixed with xylazine, medetomidine, and nitazenes — a family of synthetic opioids the agency has identified 22 distinct versions of since 2020, 21 of them now Schedule I — the federal government’s most restrictive category, reserved for substances it considers to have no accepted medical use. Nitazene detection in fentanyl-positive samples rose 17% between 2023 and 2024, per the DEA’s advisory. Unlike medetomidine, nitazenes are opioids — naloxone works on them, but because some are dramatically more potent than fentanyl, a single standard dose may not be enough. The practical harm reduction message hasn’t changed, it’s just gotten more urgent: carry more naloxone than you think you need, don’t use alone, and know that a reversal that doesn’t work the first time doesn’t mean give up — it means give more.

Kratom’s 7-OH gets carved narrower, not banned

The other major scheduling action this summer is narrower than headlines have suggested. On July 1, the DEA announced intent to temporarily place 7-hydroxymitragynine — a concentrated, chemically altered kratom derivative known as 7-OH — into Schedule I, along with three synthetic derivatives, but only above a 0.05% dry-weight threshold. Whole-leaf botanical kratom below that threshold is explicitly untouched. HHS opened a 30-day public comment period on where exactly that line should sit. The distinction matters for anyone who currently uses kratom for opioid withdrawal management or chronic pain: this is not a ban on kratom leaf. It’s a ban on the specific concentrated 7-OH products — often sold as tablets or shots at gas stations and smoke shops — that behave much more like a synthetic opioid than a plant.

HHS opened a 30-day public comment period on where exactly that line should sit.

A similar action is moving against tianeptine, an antidepressant approved in some countries but not the U.S., sold domestically as a gas-station stimulant-opioid hybrid under names like Tianna and Zaza. The DEA proposed permanently classifying it as Schedule I in July, Filter reported, following state-level bans in Pennsylvania, Connecticut, and Delaware. The FDA has linked it to hundreds of overdoses and deaths nationally.

What this means in Arizona right now

Arizona isn’t watching this from a distance. Maricopa County’s public health department issued a surveillance alert this spring flagging medetomidine detections in local overdose cases, co-occurring with fentanyl — meaning the same Philadelphia-style displacement is already showing up in the local supply, not just in East Coast drug-checking data. For treatment providers and outreach workers, that means the naloxone training you gave your team six months ago needs a refresh: the message that “one dose usually works” was true for a fentanyl-dominant supply and is no longer reliably true for one that includes medetomidine and nitazenes. If your program does street-level naloxone distribution, this week is the week to check whether your supply includes enough doses per kit for a multi-dose reversal, not the standard two. It’s also worth building a five-minute script for outreach teams and family members alike: call 911, give naloxone, and if there’s no response within two to three minutes, give another dose — don’t wait to see if the first one was “enough” the way it used to be.

None of this is a reason to stop carrying naloxone, testing what you can test, or trusting the harm reduction basics that still work. Fentanyl test strips and naloxone remain the two most effective tools available to anyone using drugs today, even against a shifting supply — they just need to be paired with the knowledge that “reversed” might now take longer and more doses than it used to. The drug supply will keep finding the next substitute, the way it has for forty years since the Analogue Act first tried to legislate its way ahead of clandestine chemistry and lost. The job of harm reduction was never to out-legislate the supply. It was, and still is, to keep people alive long enough to see whatever comes after that — one more dose, one more test strip, one more conversation that starts with “are you using alone tonight.”